ProfileGDS4814 / ILMN_1675819
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 57% 2% 33% 33% 35% 19% 15% 8% 43% 40% 49% 26% 19% 42% 37% 43% 6% 21% 3% 26% 25% 30% 47% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)53.410457
GSM780708Untreated after 4 days (C2_1)37.69262
GSM780709Untreated after 4 days (C3_1)46.29233
GSM780719Untreated after 4 days (C1_2)46.195733
GSM780720Untreated after 4 days (C2_2)46.584435
GSM780721Untreated after 4 days (C3_2)43.338119
GSM780710Trastuzumab treated after 4 days (T1_1)42.500815
GSM780711Trastuzumab treated after 4 days (T2_1)40.69618
GSM780712Trastuzumab treated after 4 days (T3_1)48.543943
GSM780722Trastuzumab treated after 4 days (T1_2)47.73340
GSM780723Trastuzumab treated after 4 days (T2_2)50.08349
GSM780724Trastuzumab treated after 4 days (T3_2)44.692326
GSM780713Pertuzumab treated after 4 days (P1_1)43.283819
GSM780714Pertuzumab treated after 4 days (P2_1)48.196142
GSM780715Pertuzumab treated after 4 days (P3_1)47.038937
GSM780725Pertuzumab treated after 4 days (P1_2)48.598543
GSM780726Pertuzumab treated after 4 days (P2_2)39.81186
GSM780727Pertuzumab treated after 4 days (P3_2)43.717121
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)38.39813
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)44.810726
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)44.571625
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)45.602430
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)49.438147